RUNX inhibitor suppresses graft‐versus‐host disease through targeting RUNX‐NFATC2 axis

Abstract

Patients with refractory graft‐versus‐host disease (GVHD) have a dismal prognosis. Therefore, novel therapeutic targets are still needed to be identified. Runt‐related transcriptional factor (RUNX) family transcription factors are essential transcription factors that mediate the essential roles in effector T cells. However, whether RUNX targeting can suppress, and GVHD is yet unknown. Here, we showed that RUNX family members have a redundant role in directly transactivating NFATC2 expression in T cells. We also found that our novel RUNX inhibitor, Chb‐M’, which is the inhibitor that switches off the entire RUNX family by alkylating agent–conjugated pyrrole‐imidazole (PI) polyamides, inhibited T‐cell receptor mediated T cell proliferation and allogenic T cell response. These were designed to specifically bind to consensus RUNX‐binding sequences (TGTGGT). Chb‐M’ also suppressed the expression of NFATC2 and pro‐inflammatory cytokine genes in vitro. Using xenogeneic GVHD model, mice injected by Chb‐M’ showed almost no sign of GVHD. Especially, the CD4 T cell was decreased and GVHD‐associated cytokines including tissue necrosis factor‐α and granulocyte‐macrophage colony‐stimulating factor were reduced in the peripheral blood of Chb‐M’ injected mice. Taken together, our data demonstrates that RUNX family transcriptionally upregulates NFATC2 in T cells, and RUNX‐NFATC2 axis can be a novel therapeutic target against GVHD.

Dissecting the regulatory network of transcription factors in T cell phenotype/functioning during GVHD and GVT

“…This alleviation was due to a decrease in CD4+ T cell proliferation and GVHD-associated cytokines. Chb-M’ also suppressed Nfatc2 expression, suggesting that the Runx/Nfatc2 axis may be a target for GVHD amelioration ( 146 ). Therefore, loss of Nfat reduced GVHD while maintaining GVT, largely through effects on migration, cytokine production, proliferation, and Treg differentiation.…”